Perrigo Company plc (NYSE:PRGO) Shares Acquired by GAMMA Investing LLC

GAMMA Investing LLC raised its position in Perrigo Company plc (NYSE:PRGO) by 5,281.6% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 103,327 shares of the company’s stock after purchasing an additional 101,407 shares during the period. GAMMA Investing LLC owned 0.08% of Perrigo worth $2,897,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in PRGO. Mirae Asset Global Investments Co. Ltd. purchased a new position in Perrigo in the 4th quarter valued at $149,000. Allspring Global Investments Holdings LLC lifted its holdings in Perrigo by 5.1% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,092,398 shares of the company’s stock valued at $28,402,000 after purchasing an additional 52,696 shares in the last quarter. Rhumbline Advisers lifted its holdings in Perrigo by 0.4% in the 4th quarter. Rhumbline Advisers now owns 370,085 shares of the company’s stock valued at $9,515,000 after purchasing an additional 1,549 shares in the last quarter. State of New Jersey Common Pension Fund D lifted its holdings in Perrigo by 13.5% in the 4th quarter. State of New Jersey Common Pension Fund D now owns 77,062 shares of the company’s stock valued at $1,981,000 after purchasing an additional 9,178 shares in the last quarter. Finally, Venturi Wealth Management LLC lifted its holdings in Perrigo by 97.8% in the 4th quarter. Venturi Wealth Management LLC now owns 4,215 shares of the company’s stock valued at $108,000 after purchasing an additional 2,084 shares in the last quarter. Hedge funds and other institutional investors own 95.91% of the company’s stock.

Perrigo Stock Down 0.5%

NYSE PRGO opened at $27.22 on Friday. Perrigo Company plc has a 52 week low of $23.14 and a 52 week high of $30.93. The company has a quick ratio of 1.77, a current ratio of 2.56 and a debt-to-equity ratio of 0.94. The business’s fifty day simple moving average is $25.98 and its 200-day simple moving average is $26.16. The firm has a market cap of $3.74 billion, a PE ratio of -23.26 and a beta of 0.46.

Perrigo (NYSE:PRGO) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.60 EPS for the quarter, topping the consensus estimate of $0.56 by $0.04. Perrigo had a positive return on equity of 7.38% and a negative net margin of 3.64%. The business had revenue of $1.04 billion for the quarter, compared to analyst estimates of $1.09 billion. During the same quarter in the previous year, the firm earned $0.29 EPS. The company’s quarterly revenue was down 3.5% compared to the same quarter last year. As a group, equities analysts anticipate that Perrigo Company plc will post 2.56 earnings per share for the current year.

Perrigo Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 17th. Investors of record on Friday, May 30th will be given a dividend of $0.29 per share. This represents a $1.16 dividend on an annualized basis and a dividend yield of 4.26%. The ex-dividend date of this dividend is Friday, May 30th. Perrigo’s payout ratio is -88.55%.

Analysts Set New Price Targets

Separately, Wall Street Zen upgraded Perrigo from a “hold” rating to a “buy” rating in a report on Saturday, May 24th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, Perrigo presently has a consensus rating of “Hold” and a consensus price target of $33.00.

Perrigo Company Profile

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.